Drug Discovery World

JUNE 22, 2023

Exosome-based drugs have the potential to address some of the limitations of genetic medicines such as gene therapy, gene editing, and RNA therapeutics by enabling safe non-immunogenic repeated delivery to cells and tissues that are currently out of reach using other drug delivery technologies.

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Financial details were not disclosed.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Drug Discovery World

JANUARY 17, 2023

They will lead research into using LNPs to deliver a gene editing tool that could delete bad genes in the photoreceptor cells and replace them with correctly functioning genes. . AAV has limited packaging capacity compared to LNPs and it can prompt an immune system response,” Sahay said.

Gene Editing 98

Gene Editing Gene Gene Therapy Genetics 98

Delveinsight

MARCH 2, 2021

HitGen & UPPTHERA Collaborate for Drug Delivery Research. HitGen has entered into a collaboration for drug discovery research with UPPTHERA to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

Drug Discovery World

FEBRUARY 16, 2023

The company’s protein nanoparticle (PNP) genetic medicine delivery platform is based on the discovery of endogenous, human proteins derived from retroelements that can self-assemble to form capsid-like structures and which can package and transfer nucleic acid cargo.

Genetics 52

Genetics Medicine Gene Editing In-Vivo 52

BioSpace

NOVEMBER 17, 2022

Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.

Gene Therapy 42

Gene Therapy Gene Gene Editing Medicine 42

The Pharma Data

SEPTEMBER 1, 2021

. “The idea of delivering such drugs essentially on demand in response to arthritis flares is extremely attractive to those of us who work with arthritis patients, because the approach could limit the adverse effects that accompany continuous high-dose administration of these drugs.” Science Advances, Sept.

Drugs 52

Drugs Engineer Drug Delivery Gene 52